Recent Updates
Recently added Catalysts
QGEN Negative Sentiment Score: 30/100

Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel, PLLP is investigating potential claims from investors of Qiagen N.V. following disappointing financial results announced on April 27, 2026. Qiagen revealed a decline of about 1% in net sales and a significant 5% drop in QuantiFERON product sales, attributed partially to reduced demand in immigration testing. Consequently, the company lowered its 2026 sales growth outlook, leading to a 10% stock price decline and prompting calls for accountability under federal securities laws.

Market Sentiment Analysis

CONCERNS & RISKS

  • Qiagen's stock price declined approximately 10% after disclosing disappointing financial results.
  • The company lowered its full-year 2026 sales growth outlook to only 1% to 2%, indicating weaker future performance.
  • A significant decline in immigration testing demand affected Qiagen's QuantiFERON product sales.

Full Press Release Details

SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE: QGEN). The investigation focuses on Qiagen’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Qiagen securities?
If you purchased Qiagen securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER.
In addition, Qiagen lowered its full-year 2026 outlook, reducing its expected sales growth to approximately 1% to 2% CER. The Company attributed the weaker performance, in part, to a “significant decline in immigration testing demand,” which impacted its QuantiFERON franchise.
Following this disclosure, Qiagen’s stock price declined approximately 10%, damaging investors.
In light of this disclosure, Johnson Fistel is investigating whether Qiagen complied with the federal securities laws. If you suffered losses from your investment in Qiagen stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Tags

Frequently Asked Questions

What is Johnson Fistel investigating regarding Qiagen?

Johnson Fistel is investigating potential claims on behalf of Qiagen investors concerning executive officers and possible recovery of investor losses.

How can I join the Qiagen investigation?

If you bought Qiagen securities and incurred losses, you can join the investigation by contacting Johnson Fistel.

Why did Qiagen's stock price decline?

Qiagen's stock dropped about 10% following a report of declining sales and a lowered sales outlook.

What factors affected Qiagen's performance?

Qiagen's weaker performance was attributed to reduced demand for immigration testing and a decline in QuantiFERON product sales.

Is there a cost to join the investigation?

No, there is no cost or obligation to you to join the investigation with Johnson Fistel.

Last updated: Apr 29, 2026